Trial Profile

A Long-Term Post-Marketing Safety Study of Yescarta® (axicabtagene ciloleucel)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

13 Dec 2022 Results by deriving data from CIBMTR registry and other study; comparing effectiveness outcomes between treatment with either axicel or chemoimmunotherapy in an elderly population in real-world settings, presented at the 64th American Society of Hematology Annual Meeting and Exposition
09 Sep 2020 New trial record
08 Sep 2020 Status changed to active no longer recruiting, according to a Center for International Blood and Marrow Transplant Research media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com